摘要
NAD(P)H:醌氧化还原酶1(NQO1)是一种抗氧化和解毒酶参与多种醌类的两电子还原。作为一种非酶基团,它参与多种肿瘤抑制基因如p53,p33和 p73α蛋白的稳定。醌氧化还原酶1在几种类型的肿瘤中高表达,与两种常见的基因多态性与癌症风险增加有关,使醌氧化还原酶1作为癌症新的治疗方法的一个潜在靶点。在这里,我们总结了醌氧化还原酶1的结构和酶学性质,以及其在肿瘤发生、发展和治疗中的作用。特别是,我们对最近的事态发展专注于在癌症相关的基因多态性功能的损失的分子基础的理解,并提出了新的方法来针对这些分子的缺陷,开发新的药物来拯救他们。我们将专注于药物治疗的目的是纠正蛋白质多态性的异常特性(如蛋白的稳定性和动力学)和调制导致丧失功能的细胞因子(如加速蛋白酶体降解)。
关键词: 癌,多态性,NAD(P)H:醌氧化还原酶1,药物分子伴侣,蛋白质动力学,蛋白酶体降解。
图形摘要
Current Drug Targets
Title:Natural Small Molecules as Stabilizers and Activators of Cancer-Associated NQO1 Polymorphisms
Volume: 17 Issue: 13
Author(s): Angel L. Pey, Clare F. Megarity, Encarnación Medina-Carmona, David J. Timson
Affiliation:
关键词: 癌,多态性,NAD(P)H:醌氧化还原酶1,药物分子伴侣,蛋白质动力学,蛋白酶体降解。
摘要: NAD(P)H: quinone oxidoreductase 1 (NQO1) is an antioxidant and detoxifying enzyme involved in the two-electron reduction of a wide variety of quinones. As a non-enzymatic function, it is involved in the stabilization of several tumour suppressors such as p53, p33 and p73α. NQO1 is overexpressed in several types of tumours, and two common polymorphisms are associated with increased cancer risk, making NQO1 a potential target for new cancer treatments. Here we review the structural and enzymological properties of NQO1, as well as its roles in cancer development and treatment. Particularly, we focus on recent developments on the understanding of the molecular basis leading to loss-of-function in cancer-associated polymorphisms, and propose new approaches to target these molecular defects to develop new pharmacological agents to rescue them. We will focus on pharmacological therapies aimed at correcting the abnormal properties of polymorphic proteins (such as protein stability and dynamics) and modulating intracellular factors leading to loss-of-function (such as accelerated proteasomal degradation).
Export Options
About this article
Cite this article as:
Angel L. Pey, Clare F. Megarity, Encarnación Medina-Carmona, David J. Timson , Natural Small Molecules as Stabilizers and Activators of Cancer-Associated NQO1 Polymorphisms, Current Drug Targets 2016; 17 (13) . https://dx.doi.org/10.2174/1389450117666160101121610
DOI https://dx.doi.org/10.2174/1389450117666160101121610 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nuclear Long Non-Coding RNAs as Epigenetic Regulators in Cancer
Current Medicinal Chemistry MEK Inhibition Increases Lapatinib Sensitivity Via Modulation of FOXM1
Current Medicinal Chemistry Eph as a Target in Inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets Advances on Semisynthesis, Total Synthesis, and Structure-Activity Relationships of Honokiol and Magnolol Derivatives
Mini-Reviews in Medicinal Chemistry The Hedgehog Signaling Pathway as a Target for Anticancer Drug Discovery
Current Topics in Medicinal Chemistry Employing New Cellular Therapeutic Targets for Alzheimers Disease: A Change for the Better?
Current Neurovascular Research Molecular Mechanisms of Cytokine-Induced Neuroprotection: NFκB and Neuroplasticity
Current Pharmaceutical Design Cellular Senescence in the Development and Treatment of Cancer
Current Pharmaceutical Design Potential Gene Therapy Strategies for Cancer Stem Cells
Current Gene Therapy M Cells Prefer Archaeosomes: An In Vitro/In Vivo Snapshot Upon Oral Gavage in Rats
Current Drug Delivery Small Molecule Inhibitors of Multidrug Resistance Gene (MDR1) Expression: Preclinical Evaluation and Mechanisms of Action
Current Cancer Drug Targets Epigenetics: Relations to Disease and Laboratory Findings
Current Medicinal Chemistry New Approaches to Target the Androgen Receptor and STAT3 for Prostate Cancer Treatments
Mini-Reviews in Medicinal Chemistry The Complexities of TGF-β Action During Mammary and Squamous Cell Carcinogenesis
Current Pharmaceutical Biotechnology The Potential of 11C-acetate PET for Monitoring the Fatty Acid Synthesis Pathway in Tumors
Current Pharmaceutical Biotechnology Biomarker Diversity, Validation and Clinical Translation: Tenets for Emergent Personalized Medicine Initiatives
Current Pharmacogenomics and Personalized Medicine Condition Optimization and Production of Extracellular l-Arginine Deiminase from Vibrio Alginolyticus 1374
Current Biotechnology Therapeutic Nanosystems for Oral Administration of Insulin
Current Pharmaceutical Biotechnology Genetics of Cancer Susceptibility
Current Genomics Follow the ATP: Tumor Energy Production: A Perspective
Anti-Cancer Agents in Medicinal Chemistry